Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Melanoma 76 Neoplasms 29 Thyroid Neoplasms 11 Neoplasm Metastasis 11 Carcinoma, Non-Small-Cell Lung 10 Thyroid Carcinoma, Anaplastic 9 Glioma 9 Brain Neoplasms 9 Multiple Myeloma 7 Colorectal Neoplasms 7 Skin Neoplasms 6 Hematologic Neoplasms 6 Thyroid Cancer, Papillary 4 Ameloblastoma 4 Lung Neoplasms 3 Histiocytosis, Langerhans-Cell 3 Glioblastoma 3 Astrocytoma 3 Rectal Neoplasms 2 Prostatic Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Oligodendroglioma 2 Neurofibroma, Plexiform 2 Neurocytoma 2 Neuroblastoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Ganglioneuroma 2

Interventions

trametinib 1 dabrafenib 1 Surgical Procedures, Operative 1 Pharmaceutical Preparations 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Malignant Neoplasm × dabrafenib × Clear all

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡